HIV envelope: challenges and opportunities for development of entry inhibitors

The HIV envelope proteins glycoprotein 120 (gp120) and glycoprotein 41 (gp41) play crucial roles in HIV entry, therefore they are of extreme interest in the development of novel therapeutics. Studies using diverse methods, including structural biology and mutagenesis, have resulted in a detailed mod...

Descripción completa

Detalles Bibliográficos
Autor principal: Caffrey, Michael
Formato: Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071980/
https://www.ncbi.nlm.nih.gov/pubmed/21377881
http://dx.doi.org/10.1016/j.tim.2011.02.001
_version_ 1782201492678115328
author Caffrey, Michael
author_facet Caffrey, Michael
author_sort Caffrey, Michael
collection PubMed
description The HIV envelope proteins glycoprotein 120 (gp120) and glycoprotein 41 (gp41) play crucial roles in HIV entry, therefore they are of extreme interest in the development of novel therapeutics. Studies using diverse methods, including structural biology and mutagenesis, have resulted in a detailed model for envelope-mediated entry, which consists of multiple conformations, each a potential target for therapeutic intervention. In this review, the challenges, strategies and progress to date for developing novel entry inhibitors directed at disrupting HIV gp120 and gp41 function are discussed.
format Text
id pubmed-3071980
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-30719802012-04-01 HIV envelope: challenges and opportunities for development of entry inhibitors Caffrey, Michael Trends Microbiol Article The HIV envelope proteins glycoprotein 120 (gp120) and glycoprotein 41 (gp41) play crucial roles in HIV entry, therefore they are of extreme interest in the development of novel therapeutics. Studies using diverse methods, including structural biology and mutagenesis, have resulted in a detailed model for envelope-mediated entry, which consists of multiple conformations, each a potential target for therapeutic intervention. In this review, the challenges, strategies and progress to date for developing novel entry inhibitors directed at disrupting HIV gp120 and gp41 function are discussed. Elsevier Ltd. 2011-04 2011-03-04 /pmc/articles/PMC3071980/ /pubmed/21377881 http://dx.doi.org/10.1016/j.tim.2011.02.001 Text en Copyright © 2011 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Caffrey, Michael
HIV envelope: challenges and opportunities for development of entry inhibitors
title HIV envelope: challenges and opportunities for development of entry inhibitors
title_full HIV envelope: challenges and opportunities for development of entry inhibitors
title_fullStr HIV envelope: challenges and opportunities for development of entry inhibitors
title_full_unstemmed HIV envelope: challenges and opportunities for development of entry inhibitors
title_short HIV envelope: challenges and opportunities for development of entry inhibitors
title_sort hiv envelope: challenges and opportunities for development of entry inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071980/
https://www.ncbi.nlm.nih.gov/pubmed/21377881
http://dx.doi.org/10.1016/j.tim.2011.02.001
work_keys_str_mv AT caffreymichael hivenvelopechallengesandopportunitiesfordevelopmentofentryinhibitors

Ejemplares similares